

References

Abdol, H. Mallet, V. Pol, S. Fontanet, A.: serum Alpha-fetoprotein predict treatment outcome in chronic HCV patients regardless of HCV Genotype. PLoS ONE; 3:6, e2391,1-4. 2008.

Adrian, M. Di Bisceglie,: Predictors of a sustained virologic response following treatment for chronic hepatitis C virus infection , uptodate (medical program version19.1); 2011.

Afdhal, N.H., Dieterich, D.T., Pockros, P.J., Schiff, E.R., Shiffman, M.L., Sulkowski, M.S., Wright, T., Younossi, Z., Goon, BL, Tang, K.L., Bowers, P.J.; Proactive Study Group: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterol;126:1302-11. 2004.

Afdhal, N.H., McHutchison, J.G., Zeuzem, S. Mangia, A. Pawlotsky, J.M., Murray, J.S., Shianna, K.V., Tanaka, Y., Thomas, D.L., Booth, D.R., Goldstein, D.B.; Pharmacogenetics and Hepatitis C Meeting Participants.: Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology; 53:336-45. 2011.

Apinya Leerapun, Sri V. Suravarapu, John P. Bida, aynell J. Clark, Elizabeth L. Sanders, Teresa A. Mettler, Linda M. Stadheim,

- Ileana Aderca, Catherine D. Moser, David M. Nagorney, Nicholas F. LaRusso, Piet C. de Groen, K. V. Narayanan Menon, Konstantinos N. Lazaridis, Gregory J. Gores, Michael R. Charlton, Rosebud O. Roberts, Terry M. Therneau, Jerry A. Katzmann, and Lewis R. Roberts:** The utility of AFP-L3 in the diagnosis of hepatocellular carcinoma: evaluation in a U.S. Referral population. *Gastroenterol Hepatol.*; 5(3): 394–267. 2007.
- Alter, M.J.:** Epidemiology of hepatitis C in the West. *Sem Liver Dis*;15:5-14. 1995.
- Ascione, A., De, Luca, M., Tartaglione, M.T., Lampasi, F., Di, Costanzo, G.G., Lanza, A.G., Picciotto, F.P., Marino-Marsilia, G., Fontanella, L., Leandro, G.:** Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. *Gastroenterol*;138:116-22. 2010.
- Bader, D., Riskin, A., Vafsi, O., Tamir, A., Peskin, B., Israel, N., Merksamer, R., Dar, H., David, M.:** Alpha-fetoprotein in the early neonatal period--a large study and review of the literature". *Clin. Chim. Acta* 349 (1–2): 15–23.2004.
- Backus, L., Boothroyd, D.B., Phillips, B.R., Mole, L.A.:** Impact of sustained virologic response to pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: The US Department of Veterans Affairs' experience. *Hepatology*; 52:428A.2010.

Ball, D., Rose, E., Alpert, E.: Alpha-fetoprotein levels in normal adults".
Am. J. Med. Sci. 303 (3): 157–9.1992.

Bayati, N., Silverman, A.L., Gordon, S.C.: Serum alpha-fetoprotein
levels and liver histology in patients with chronic hepatitis Am. J.
Gastroenterol.,93: 2452-2456.1998.

**Berg, T., Kronenberger, B., Hinrichsen, H., Gerlach, T., Buggisch, P.,
Herrmann, E., Spengler, U., Goeser, T., Nasser, S., Wurstthorn,
K., Pape, G.R., Hopf, U., Zeuzem, S.:** Triple therapy with
amantadine in treatment-naïve patients with chronic hepatitis C: a
placebo-controlled trial. Hepatology;37:1359-67. 2003.

**Berg, T., Sarrazin, C., Herrmann, E., Hinrichsen, H., Gerlach, T.,
Zachoval, R., Wiedenmann, B., Hopf, U., Zeuzem, S.:** Prediction
of treatment outcome in patients with chronic hepatitis C:
significance of baseline parameters and viral dynamics during
therapy. Hepatology 37: 600–9.2003.

**Berg, T., Weich, V., Teuber, G., Klinker, H., Möller B., Rasenack, J.,
Hinrichsen, H., Gerlach, T., Spengler, U., Buggisch, P., Balk, H.,
Zankel, M., Neumann, K., Sarrazin, C., Zeuzem, S.:**
Individualized treatment strategy according to early viral kinetics in
hepatitis C virus type 1-infected patients. Hepatology;50:369-77.
2009.

- Blair, J.I., Carachi, R., Gupta, R., Sim, F.G., McAllister, E.J., Weston, R. :** Plasma alpha fetoprotein reference ranges in infancy: effect of prematurity." *Arch. Dis. Child.* 62 (4): 362–9.1987.
- Blohm, M.E., Vesterling-Hörner, D., Calaminus, G., Göbel, U.:** Alpha - fetoprotein (AFP) reference values in infants up to 2 years of age." *Pediatric hematology and oncology* 15 (2): 135–42.1998.
- Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., Maes, M.:** Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. *J Clin Psychopharmacol*;22:86-90. 2002.
- Bronowicki, J.P., Ouzan, D., Asselah, T., Desmorat, H., Zarski, J.P., Foucher, J., Bourlière, M., Renou, C., Tran, A., Melin, P., Hézode, C., Chevalier, M., Bouvier-Alias, M., Chevaliez, S., Montestruc, F., Lonjon-Domanec, I., Pawlotsky, J.M.:** Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. *Gastroenterology*; 131:1040. 2006.
- Bruchfeld, A., Lindahl, K., Schvarcz, R., Stahle, L.:** Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. *Ther Drug Monit*;24:701-08. 2001.

Capuron, L., Ravaud, A., Neveu, P.J., Miller, A.H., Maes, M., Dantzer, R.: Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. *Mol Psychiatry*;7:468-73. 2002.

Cardoso, A.C., Moucari, R., Figueiredo-Mendes, C., Ripault, M.P., Giuily, N., Castelnau, C., Boyer, N., Asselah, T., Martinot-Peignoux, M., Maylin, S., Carvalho-Filho, R.J., Valla, D., Bedossa, P., Marcellin, P.: Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. *J Hepatol*;52:652.2010.

Caruntu, F.A., Benea, L.: Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. *Journal of Gastrointestinal and Liver Diseases* 15 (3): 249–56. 2006.

cdc.gov:http://en.wikipedia.org/wiki/File:Hepatitis_C_infection_by_source_(CDC)_-_en.svg, 2009.

Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M.: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 244 (4902): 359–62.1989.

- Christiansen, M., Høgdall, C.K., Høgdall, E.V.:** Alpha-fetoprotein in human fetal cerebrospinal fluid. *Clinica chimica acta; international journal of clinical chemistry* 291 (1): 35–41. 2000.
- Chu, C., Hwang, S., Luo, J., Lai, C., Tsay, S., Li, C., Wu, J., Chang, F., Lee, S:** Clinical, virologic and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. *J. Clin Gastroent.*,32(3): 240-244. 2001.
- Clark, P.J., Thompson, A.J., Zhu, M.:** IL28B genetic polymorphism has genome wide significant associations with serum low density lipoprotein levels and hepatic steatosis in patients with genotype 1 chronic hepatitis C (CHC). *Hepatology*; 52:439A. 2010.
- Coakley, J., Kellie, S.J., Nath, C., Munas, A., Cooke-Yarborough, C.:** Interpretation of alpha-fetoprotein concentrations in cerebrospinal fluid of infants". *Annals of clinical biochemistry* 42 (Pt 1): 24–9. 2005.
- Conjeevaram, H.S., Fried, M.W., Jeffers, L.J., Terrault, N.A., Wiley-Lucas, T.E., Afdhal, N., Brown, R.S., Belle, S.H., Hoofnagle, J.H., Kleiner, D.E., Howell, C.D.; Virahep-C Study Group.:** Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. *Gastroenterology*;131:470. 2006.

Cornberg, M., Hadem, J., Herrmann, E., Schuppert, F., Schmidt, H.H., Reiser, M., Marschal, O., Steffen, M., Manns, M.P., Wedemeyer, H.: Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. *J Hepatol*;44:291-301. 2006.

Cornberg, M., Wedemeyer, H., Manns, M.P.: Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. *Curr Gastroenterol Rep*;4:23-30. 2002.

Crocoli, A., Madafferi, S., Jenkner, A., Zaccara, A., Inserra, A.: Elevated serum alpha-fetoprotein in Wilms tumor may follow the same pattern of other fetal neoplasms after treatment: evidence from three cases.". *Pediatr Surg Int* 24 (4): 499–502.2007.

Dabeva, M.D., Shafritz, D.A.: Activation, proliferation, and differentiation of progenitor cells into hepatocytes in the D-galactosamine model of liver regeneration. *Am J Pathol* 143: 1606–20.1993.

Dalgard, O., Bjørø, K., Hellum, K.B., Myrvang, B., Ritland, S., Skaug, K., Raknerud, N., Bell, H.: Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. *Hepatol* ;40:1260-65.2004.

- Dalgard, O., Bjørø, K., Ring-Larsen, H., Bjornsson, E., Holberg-Petersen, M., Skovlund, E., Reichard, O., Myrvang, B., Sundelöf, B., Ritland, S., Hellum, K., Frydén, A., Florholmen, J., Verbaan, H.; North-C Group.:** Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. *Hepatology*; 47:35-42. 2008.
- Davis, G.L., Balart, L.A., Schiff, E.R.:** Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. *N Engl J Med*;321:1501-6. 1989.
- Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J., Albrecht, J.:** Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*;38:645-52. 2003.
- de, Lédínghe, V., Trimoulet, P., Mannant, P.R., Dumas, F., Champbenoît, P., Baldit, C., Foucher, J., Faure, M., Vergniol, J., Castéra, L., Bertet, J., Fleury, H., Couzigou, P., Bernard, P.H.:** Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). *J Hepatology*;46:19-25. 2007.
- Di, Bisceglie, A.M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S.M., Hoofnagle, J.H.:** Recombinant interferon alfa therapy for chronic hepatitis C.

A randomized, double-blind, placebo-controlled trial. *N Engl J Med*;321:1506-10. 1989.

Di, Bisceglie, A.M., Shiffman, M.L., Everson, G.T., Lindsay, K.L., Everhart, J.E., Wright, E.C., Lee, W.M., Lok, A.S., Bonkovsky, H.L., Morgan, T.R., Ghany, M.G., Morishima, C., Snow, K.K., Dienstag, J.L.; HALT-C Trial Investigators.: Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. *N Engl J Med*;359:2429-41. 2008.

Dieperink, E., Willenbring, M., Ho, S.B.: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. *Am J Psychiatry*;157:867-76. 2000.

Dubuisson, J.: Hepatitis C virus proteins". *World J. Gastroenterol.* 13 (17): 2406–15.2007.

Duffy, M.J.: Evidence for the clinical use of tumour markers". *Ann. Clin. Biochem.* 41 (Pt 5): 370–7. 2004.

Duffy, M.J., Crown, J.: A personalized approach to cancer treatment: how biomarkers can help". *Clin. Chem.* 54 (11): 1770–9. 2008.

Dumortier, J., Scoazec, J.Y., Chevallier, P., Boillot, O.: Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. *J Hepatol*;40:669-74. 2004.

Entrez Gene: Alpha-fetoprotein :

<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=174>.

Everson, G.T.: Treatment of chronic hepatitis C in patients with decompensated cirrhosis. *Rev Gastroenterol Disord*;4:S31-38. 2004.

Ferenci, P., Fried, M.W., Shiffman, M.L., Smith, C.I., Marinos, G., Gonçalves, F.L. Jr, Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxì, A., Chaneac, M., Reddy, K.R.: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. *J Hepatol*; 43:425. 2005.

Ferenci, P., Laferl, H., Scherzer, T.M., Gschwantler, M., Maieron, A., Brunner, H., Stauber, R., Bischof, M., Bauer, B., Datz, C., Löschenberger, K., Formann, E., Staufer, K., Steindl-Munda, P.; Austrian Hepatitis Study Group.: Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology*; 135:451. 2008.

Fellay, J., Thompson, A.J., Ge, D., Gumbs, C.E., Urban, T.J., Shianna, K.V., Little, L.D., Qiu, P., Bertelsen, A.H., Watson, M., Warner, A., Muir, A.J., Brass, C., Albrecht, J., Sulkowski, M., McHutchison, J.G., Goldstein, D.B.: ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature*;464:405-8. 2010.

Forns, X., García-Retortillo, M., Serrano, T., Feliu, A., Suarez, F., de la, Mata, M., García-Valdecasas, J.C., Navasa, M., Rimola, A., Rodés, J.: Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. *J Hepatol*;39:389-96. 2003.

Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Gonçalves, F.L. Jr, Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*;347:975.2002.

Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., Heinzen, E.L., Qiu, P., Bertelsen, A.H., Muir, A.J., Sulkowski, M., McHutchison, J.G., Goldstein, D.B.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature*; 461:399. 2009.

- Gebo, K.A., Herlong, H.F., Torbenson, M.S., Jenckes, M.W., Chander, G., Ghanem, K.G., El-Kamary, S.S., Sulkowski, M., Bass, E.B.:** Role of liver biopsy in management of chronic hepatitis C: a systematic review. *Hepatology*;36(5 Suppl 1):S161-72. 2002
- Gerlach, J.T., Diepolder, H.M., Zachoval, R., Gruener, N.H., Jung, M.C., Ulsenheimer, A., Schraut, W.W., Schirren, C.A., Waechtler, M., Backmund, M., Pape, G.R.:** Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterol*;125:80-88. 2003.
- Germain, L., Noel, M., Gourdeau, H., Marceau, N.:** Promotion of growth and differentiation of rat ductular oval cells in primary culture. *Cancer Res* 48: 368–78.1988.
- Gitto, S., Micco, L., Conti, F., Andreone, P., Bernardi, M.:** Alcohol and viral hepatitis: A mini-review. *Dig Liver Dis*;41:67-70. 2009.
- GrahamColm:**http://en.wikipedia.org/wiki/File:HCV_genome.png, 2007.
- GrahamColm:**http://en.wikipedia.org/wiki/File:Hepatitis_C_serology.png, 2008.
- GrahamColm:**http://en.wikipedia.org/wiki/File:HCV_structure.png, 2008.
- Hadziyannis, S.J., Sette, H. Jr, Morgan, T.R., Balan, V., Diago, M.,**

- Marcellin, P., Ramadori, G., Bodenheimer, H. Jr, Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M.; PEGASYS International Study Group.:** Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*;140:346.2004.
- Hahn, J.A. :** Sex, Drugs, and Hepatitis C Virus. *J Infect Dis* 195 (11): 1556–9. 2007.
- Hraber, P., Kuiken, C., Yusim, K.:** Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. *Hepatology*;46:1713-21. 2007.
- Harper, M.E., Dugaiczky, A. :** Linkage of the evolutionarily-related serum albumin and alpha-fetoprotein genes within q11-22 of human chromosome 4. *American journal of human genetics* 35 (4): 565–72.1983.
- Harrison, S.A., Rossaro, L., Hu, K.Q., Patel, K., Tillmann, H., Dhaliwal, S., Torres, D.M., Koury, K., Goteti, V.S., Noviello, S., Brass, C.A., Albrecht, J.K., McHutchison, J.G., Sulkowski, M.S.:** Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. *Hepatology*; 52:864. 2010.
- Hendy, Abdoul., Vincent, Mallet, Stanislas, Pol., Arnaud, Fontanet,:** Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype, *PLoS ONE*, 3:4. 2008.

- Herbert, L., Bonkovsky, M.D., Savant, Mehta, M.d.:** Hepatitis C: A review and update, *Journal of the American Academy of Dermatology* 44;2, pp 159-182.2001.
- Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.P., Bourlière, M., Gharakhanian, S., Bengtsson, L., McNair, L., George, S., Kieffer, T., Kwong, A., Kauffman, R.S., Alam, J., Pawlotsky, J.M., Zeuzem, S.; PROVE2 Study Team.:** Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med*;360:1839-50. 2009.
- Houghton, M.:** The long and winding road leading to the identification of the hepatitis C virus. *Journal of Hepatology* 51 (5): 939–48. 2009.
- Jacobson, I.M., Brown, R.S. Jr, McCone, J., Black, M., Albert, C., Dragutsky, M.S., Siddiqui, F.A., Hargrave, T., Kwo, P.Y., Lambiase, L., Galler, G.W., Araya, V., Freilich, B., Harvey, J., Griffel, L.H., Brass, C.A.; WIN-R Study Group.:** Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. *Hepatology*; 46:982. 2007.
- Jacobson, I.M., Brown, R.S. Jr, Freilich, B., Afdhal, N., Kwo, P.Y., Santoro, J., Becker, S., Wakil, A.E., Pound, D., Godofsky, E.,**

- Strauss, R., Bernstein, D., Flamm, S., Pauly, M.P., Mukhopadhyay, P., Griffel, L.H., Brass, C.A.; WIN-R Study Group.:** Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. *Hepatology*; 46:971. 2007.
- Jacobson, I.M., Gonzalez, S.A., Ahmed, F., Lebovics, E., Min, A.D., Bodenheimer, H.C. Jr, Esposito, S.P., Brown, R.S. Jr, Bräu, N., Klion, F.M., Tobias, H., Bini, E.J., Brodsky, N., Cerulli, M.A., Aytaman, A., Gardner, P.W., Geders, J.M., Spivack, J.E., Rahmin, M.G., Berman, D.H., Ehrlich, J., Russo, M.W., Chait, M., Rovner, D., Edlin, B.R.:** A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. *Am J Gastroenterol*;100:2453-62. 2005.
- Jacobson, I.M., McHutchison, J.G., Dusheiko, G.:** Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 advance study. *Hepatology*;52:S427. 2010.
- Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., Manns, M.P.; German Acute Hepatitis C Therapy Group.:** Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med*;345:1452-57. 2001.

- Janssen, H.L., Brouwer, J.T., van, der, Mast, R.C., Schalm, S.W.:**
Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol;21:241-43. 1994.
- Jassam, N., Jones, C.M., Briscoe, T., Horner, J.H.:** The hook effect: a need for constant vigilance". Ann. Clin. Biochem. 43 (Pt 4): 314–7.2006.
- Jeffers, L.J., Cassidy, W., Howell, C.D., Hu, S., Reddy, K.R.:**
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology; 39:1702. 2004.
- Jensen, D. :**A New Era of Hepatitis C Therapy Begins. N Engl J Med. 364 (13): 1272–1273.2011.
- Johnson, P.J.:** The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma.Clin Liver Dis.;5(1):145-59. 2001.
- Jubin, R.:** Hepatitis C IRES: translating translation into a therapeutic target". Curr. Opin. Mol. Ther. 3 (3): 278–87.2001.
- Kamath, P.S., Kim, W.R.:**The model for end-stage liver disease (MELD). Hepatology 45 (3): 797–805. 2007.

- Karmochkine, M., Carrat, F., Dos, Santos, O., Cacoub, P., Raguin, G.:** A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. *Journal of Viral Hepatitis* 13 (11): 775–82. 2006.
- Kato, N.:** Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation". *Microb. Comp. Genomics* 5 (3): 129–51. 2000.
- Kau, A., Vermehren, J., Sarrazin, C.:** Treatment predictors of a sustained virologic response in hepatitis B and C. *J Hepatol*;49:634. 2008.
- Khattab, M., Eslam, M., Sharwae, M.A., Shatat, M., Ali, A., Hamdy, L.:** Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. *Am J Gastroenterol*; 105:1970. 2010.
- Kinoshita, Y., Tajiri, T., Souzaki, R., Tatsuta, K., Higashi, M., Izaki, T., Takahashi, Y., Taguchi, T.:** Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study". *J. Pediatr. Hematol. Oncol.* 30 (6): 447–50. 2008.
- Kim, do, Y., Paik, Y.H., Ahn, S.H., Youn, Y.J., Choi, J.W., Kim, J.K., Lee, K.S., Chon, C.Y., Han, K.H.:** PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.". *Oncology* 72 Suppl 1: 52–7. 2007.

Kraus, M.R., Schafer, A., Al-Taie, O., Scheurlen, M.: Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. *J Viral Hepat*;12:96-100. 2005.

Kraus, M.R., Schafer, A., Scheurlen, M.: Paroxetine for the prevention of depression induced by interferon alfa. *N Engl J Med*;345:375-6. 2001.

Kraus, M.R., Schäfer, A., Schöttker, K., Keicher, C., Weissbrich, B., Hofbauer, I., Scheurlen, M.: Therapy of interferon-induced depression in chronic hepatitis C with citalopram: A randomized, double-blind, placebo-controlled study. *Gut*;57:531-6. 2008.

Lam, K.D., Trinh, H.N., Do, S.T., Nguyen, T.T., Garcia, R.T., Nguyen, T., Phan, Q.Q., Nguyen, H.A., Nguyen, K.K., Nguyen, L.H., Nguyen, M.H. : Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naïve chronic hepatitis C genotype 6. *Hepatology*;52:1573.2010.

Lazarevich, N.L: Molecular mechanisms of alpha-fetoprotein gene expression. *Biochemistry*,65: 117-133.2000.

Lee, P.I., Chang, M.H., Chen, D.S., Lee, C.Y. : Serum alpha-fetoprotein levels in normal infants: a reappraisal of regression analysis and sex difference". J. Pediatr. Gastroenterol. Nutr. 8 (1): 19–25.1989.

Lim, Y.S., Kim, W.R.: The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis;12:733-46. 2008.

Lindsay, K.L., Morishima, C., Wright, E.C., Dienstag, J.L., Shiffman, M.L., Everson, G.T., Lok, A.S., Bonkovsky, H.L., Lee, W.M., Morgan, T.R., Ghany, M.G.; HALT-C Trial.: Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol; 6:234. 2008.

Lisker-Melman, M., Di, Bisceglie, A.M., Usala, S.J., Weintraub, B., Murray, L.M., Hoofnagle, J.H.: Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterol;102:2155-60. 1992.

Lock, G., Dirscherl, M., Obermeier, F., Gelbmann, C.M., Hellerbrand, C., Knöll, A., Schölmerich, J., Jilg, W.: Hepatitis C — contamination of toothbrushes: myth or reality?. J. Viral Hepat. 13 (9): 571–3. 2006.

- Malaguarnera, M., Laurino, A., Di, Fazio, I., Pistone, G., Castorina, M., Guccione, N., Rampello, L.:** Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. *J Interferon Cytokine Res*;21:273-78. 2001.
- Males, S., Gad, R.R., Esmat, G., Abobakr, H., Anwar, M., Rekacewicz, C., El Hoseiny, M., Zalata, K., Abdel-Hamid, M., Bedossa, P., Pol, S., Mohamed, M.K., Fontanet, A.:** Serum alpha foetoprotein level predicts treatment outcome in chronic hepatitis C. *Antiviral Therapy* 12: 797–803.2007.
- Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., Romano, M., Zechini, F., Sogari, F., Spirito, F., Andriulli, A.:** Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med*;352:2609-17. 2005.
- Mangia, A., Thompson, A.J., Santoro, R.:** An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. *Gastroenterology*; 139:821. 2010.
- Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K.:** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*;358:958-65. 2001.

Manns, M., Zeuzem, S., Sood, A., Lurie, Y., Cornberg, M., Klinker, H., Buggisch, P., Rössle, M., Hinrichsen, H., Merican, I., Ilan, Y., Mauss, S., Abu-Mouch, S., Horban, A., Müller, T.H., Welsch, C., Chen, R., Faruqi, R., Pedicone, L.D., Wedemeyer, H.: Reduced Dose and Duration of Peginterferon Alfa-2b+Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (Redd 2/3 Trial). *J Hepatol*;50:S59-S59. 2009.

Manns, M.P., Wedemeyer, H., Cornberg, M.: Treating viral hepatitis C: efficacy, side effects, and complications. *Gut*;55:1350–59. 2006.

Marcellin, P., Craxi, A., Brandao-Mello, C.E.: A 72-Week Treatment Duration with Peginterferon Alfa-2a Plus Ribavirin Has a Favorable Risk:Benefit Ratio in Non-Responders to Pegylated Interferon Alfa-2b Plus Ribavirin: Findings of the Multinational Repeat Study. *Hepatol*;48:1147A-1147A. 2008.

Marcellin, P., Forns, X., Goeser, T., Ferenci, P., Nevens, F., Carosi, G., Drenth, J.P., Serfaty, L., De, Backer, K., Van, Heeswijk, R., Luo, D., Picchio, G., Beumont, M.: Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C. *Gastroenterology* 2010.

McCarthy, J.J., Li, J.H., Thompson, A., Suchindran, S., Lao, X.Q., Patel, K., Tillmann, H.L., Muir, A.J., McHutchison, J.G.:

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. *Gastroenterology*; 138:2307. 2010.

McHutchison, J.G., Dusheiko, G., Shiffman, M.L., Rodriguez-Torres, M., Sigal, S., Bourliere, M., Berg, T., Gordon, S.C., Campbell, F.M., Theodore, D., Blackman, N., Jenkins, J., Afdhal, N.H.; TPL102357 Study Group.: Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med*;357:2227-36. 2007.

McHutchison, J.G., Everson, G.T., Gordon, S.C., Jacobson, I.M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., Muir, A.J.; PROVE1 Study Team.: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med*;360:1827-38. 2009.

McHutchison, J.G., Manns, M.P., Muir, A.J., Terrault, N.A., Jacobson, I.M., Afdhal, N.H., Heathcote, E.J., Zeuzem, S., Reesink, H.W., Garg, J., Bsharat, M., George, S., Kauffman, R.S., Adda, N., Di Bisceglie, A.M.; PROVE3 Study Team.: Telaprevir for previously treated chronic HCV infection. *N Engl J Med*;362:1292-303. 2010.

McHutchison, J.G., Manns, M., Patel, K., Poynard, T., Lindsay, K.L., Trepo, C., Dienstag, J., Lee, W.M., Mak, C., Garaud, J.J.,

- Albrecht, J.K.; International Hepatitis Interventional Therapy Group.:** Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology*; 123:1061. 2002.
- Mizejewski, G.J.:** Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. *Experimental biology and medicine* (Maywood, N.J.) 226 (5): 377–408. 2001.
- Montes-Cano, M.A., García-Lozano, J.R., Abad-Molina, C., Romero-Gómez, M., Barroso, N., Aguilar-Reina, J., Núñez-Roldán, A., González-Escribano, M.F.:** Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. *Hepatology*; 52:33. 2010.
- Moreno, C., Deltenre, P., Pawlotsky, J.M., Henrion, J., Adler, M., Mathurin, P.:** Shortened treatment duration in treatment-naïve genotype 1 HCV patients with rapid virological response: a meta-analysis. *J Hepatol*; 52:25. 2010.
- Morishima, C., Morgan, T.R., Everhart, J.E., Wright, E.C., Shiffman, M.L., Everson, G.T., Lindsay, K.L., Lok, A.S., Bonkovsky, H.L., Di, Bisceglie, A.M., Lee, W.M., Dienstag, J.L., Ghany, M.G., Gretch, D.R.; HALT-C Trial Group.:** HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. *Hepatology*; 44:360. 2006.

- Morgan, T.R., Ghany, M.G., Kim, H.Y., Snow, K.K., Shiffman, M.L., De, Santo, J.L., Lee, W.M., Di, Bisceglie, A.M., Bonkovsky, H.L., Dienstag, J.L., Morishima, C., Lindsay, K.L., Lok, A.S.; HALT-C Trial Group.:** Outcome of sustained virological responders with histologically advanced chronic hepatitis C. *Hepatology*;52:833.2010.
- MR. Abdelgawad, M. Abdel-Wahab , M. Mostafa:** Evaluation of Serum Alpha-fetoprotein Levels in Chronic Hepatitis C Patients With or Without Hepatocellular Carcinoma,BioInfoBank Institute. 2006.
- Muir, A.J., Bornstein, J.D., Killenberg, P.G.:** Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. *N Engl J Med*;350:2265.2004.
- Murray, M.J., Nicholson, J.C.:** α -Fetoprotein.*Arch Dis Child Educ Pract Ed.*;96(4):141-7. 2011.
- Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., Greiner, K., Nemeroff, C.B., Miller, A.H.:** Paroxetine for the prevention of depression induced by high-dose interferon alfa. *N Engl J Med*;344:961-66. 2001.
- Nakata, K., Motomura, M., Nakabayashi, H., Ido, A., Tamaoki, T.:** A possible mechanism of in verse development regulation of alpha-

fetoprotein and albumin genes. J. Biol. Chem., 267: 1331-1334.1992.

Neff, G.W., Montalbano, M., O'Brien, C.B., Nishida, S., Safdar, K., Bejarano, P.A., Khaled, A.S., Ruiz, P., Slapak-Green, G., Lee, M., Nery, J., De, Medina, M., Tzakis, A., Schiff, E.R.: Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation;78:1303-07. 2004.

NIH Consensus Development Conference on Management of Hepatitis C: 2002.

O. G. Pybus,A. J. Drummond, T. Nakano, B. H. Robertson, and A. Rambaut: The Epidemiology and Iatrogenic Transmission of Hepatitis C Virus in Egypt: A Bayesian Coalescent Approach, Mol. Biol. Evol. 20(3):381–387. 2003.

Ohama, K., Nagase, H., Ogino, K., Tsuchida, K., Tanaka, M., Kubo, M., Horita, S., Kawakami, K., Ohmori, M.:Alpha-fetoprotein (AFP) levels in normal children.". European Journal of Pediatric Surgery 7 (5): 267–9.1997.

- Ohguchi, S., Nakatsukasa, H., Higashi, T., Ashida, K., Nouse, K., Ishizaki, M., Hino, N., Kobayashi, Y., Uematsu, S., Tsuji, T.:** Expression of a-fetoprotein and albumin in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy. *Hepatology*, 27: 599-706.1998.
- Op, De, Beeck, A., Dubuisson, J.:** Topology of hepatitis C virus envelope glycoproteins". *Rev. Med. Virol.* 13 (4): 233–41.2003.
- Pariante, C.M., Landau, S., Carpiniello, B.:** Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis. *N Engl J Med*;347:148-49. 2002.
- Pascual, M., Perrin, L., Giostra, E., Schifferli, J.A.:** Hepatitis C virus in patients with cryoglobulinemia type II. *The Journal of Infectious Diseases* 162 (2): 569–70. 1990.
- Paul, S.B., Gulati, M.S., Sreenivas, V., Madan, K., Gupta, A.K., Mukhopadhyay, S., Acharya, S.K.:** Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein.". *Oncology* 72 Suppl 1: 117–23.2007.

Pockros, P.J., Shiffman, M.L., Schiff, E.R., Sulkowski, M.S., Younossi, Z., Dieterich, D.T., Wright, T.L., Mody, S.H., Tang, K.L., Goon, B.L., Bowers, P.J., Leitz, G., Afdhal, N.H.; PROACTIVE Study Group.:and the PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. *Hepatology*;40:1450-8. 2004.

Poustchi, H., Negro, F., Hui, J., Cua, I.H., Brandt, L.R., Kench, J.G., George, J.: Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. *J Hepatology*; 48:28. 2008.

Poynard, T., Bedossa, P., Opolon, P.:history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet*;349:825-32. 1997.

Poynard, T., Colombo, M., Bruix, J., Schiff, E., Terg, R., Flamm, S., Moreno-Otero, R., Carrilho, F., Schmidt, W., Berg, T., McGarrity, T., Heathcote, E.J., Gonçalves, F., Diago, M., Craxi, A., Silva, M., Bedossa, P., Mukhopadhyay, P., Griffel, L., Burroughs, M., Brass, C., Albrecht, J.; Epic Study Group.: Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. *Gastroenterology* ;136:1618-28,1612.2009.

- Poynard, T., McHutchison, J., Goodman, Z., Ling, M.H., Albrecht, J.:**
Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. *Hepatology* 31: 211–8. 2000.
- Raison, C.L., Woolwine, B.J., Demetrashvili, M.F., Borisov, A.S., Weinreib, R., Staab, J.P., Zajecka, J.M., Bruno, C.J., Henderson, M.A., Reinus, J.F., Evans, D.L., Asnis, G.M., Miller, A.H.:**
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. *Aliment Pharmacol Ther*;25:1163-74. 2007.
- Ramcharran, D., Wahed, A.S., Conjeevaram, H.S., Evans, R.W., Wang, T., Belle, S.H., Yee, L.J.; Virahep-C Study Group.:** Associations between serum lipids and hepatitis C antiviral treatment efficacy. *Hepatology*; 52:854. 2010.
- Rao, G.A., Pandya, P.K.:** Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. *Gastroenterology*; 140:144. 2011.
- Rauch, A., Kotalik, Z., Descombes, P., Cai, T., Di, Iulio, J., Mueller, T., Bochud, M., Battegay, M., Bernasconi, E., Borovicka, J., Colombo, S., Cerny, A., Dufour, J.F., Furrer, H., Günthard, H.F., Heim, M., Hirschel, B., Malinverni, R., Moradpour, D., Müllhaupt, B., Witteck, A., Beckmann, J.S., Berg, T., Bergmann,**

- S., Negro, F., Telenti, A., Bochud, P.Y.; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study.:** Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology*; 138:1338. 2010.
- Ryan, K.J., Ray, C.G.:** Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 551–2.2004.
- Rebischung, C., Pautier, P., Morice, P., Lhomme, C., Duvillard, P.:** Alpha-fetoprotein production by a malignant mixed Müllerian tumor of the ovary.". *Gynecol. Oncol.* 77 (1): 203–5.2000.
- Reddy, K.R., Shiffman, M.L., Morgan, T.R., Zeuzem, S., Hadziyannis, S., Hamzeh, F.M., Wright, T.L., Fried, M.:** Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. *Clin Gastroenterol Hepatol*; 5:124. 2007.
- Reddy, K.R., Shiffman, M.L., Rodriguez-Torres, M., Cheinquer, H., Abdurakhmanov, D., Bakulin, I., Morozov, V., Silva, G.F., Geyvandova, N., Stanciu, C., Rabbia, M., McKenna, M., Thommes, J.A., Harrison, S.A.; PROGRESS Study Investigators.:** Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. *Gastroenterology*; 139:1972. 2010.

- Renault, P.F., Hoofnagle, J.H., Park, Y., Mullen, K.D., Peters, M., Jones, D.B., Rustgi, V., Jones, E.A.:** Psychiatric complications of long-term interferon alfa therapy. *Arch Intern Med*;147:1577-80. 1987.
- Richard J. Johnson, David R. Gretch, Hideaki Yamabe, Jaime Hart, Carlos E. Bacchi, Peter Hartwell, William G. Couser, Lawrence Corey, Mark H. Wener, Charles E. Alpers, and Richard Willson:** Membranoproliferative glomerulonephritis associated with hepatitis C virus infection". *N Engl J Med* 328 (7): 465–70. 1993.
- Rodriguez-Luna, H., Khatib, A., Sharma, P., De, Petris, G., Williams, J.W., Ortiz, J., Hansen, K., Mulligan, D., Moss, A., Douglas, D.D., Balan, V., Rakela, J., Vargas, H.E.:** Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. *Transplantation*;77:190-94. 2004.
- Rodriguez-Torres, M., Jeffers, L.J., Sheikh, M.Y., Rossaro, L., Ankoma-Sey, V., Hamzeh, F.M., Martin, P.; Latino Study Group.:** Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. *N Engl J Med*; 360:257. 2009.
- Romero-Gómez, M., Del, Mar, Vilorio, M., Andrade, R.J., Salmerón, J., Diago, M., Fernández-Rodríguez, C.M., Corpas, R., Cruz, M.,**

Grande, L., Vázquez, L., Muñoz-De-Rueda, P., López-Serrano, P., Gila, A., Gutiérrez, M.L., Pérez, C., Ruiz-Extremera, A., Suárez, E., Castillo, J.: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*; 128:636. 2005.

Romero-Gómez, M., Diago, M., Andrade, R.J., Calleja, J.L., Salmerón, J., Fernández-Rodríguez, C.M., Solà, R., García-Samaniego, J., Herrerías, J.M., De la Mata, M., Moreno-Otero, R., Nuñez, O., Oliveira, A., Durán, S., Planas, R.; *Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group.:* Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. *Hepatology*; 50:1702. 2009.

Rumi, M.G., Aghemo, A., Prati, G.M., D'Ambrosio, R., Donato, M.F., Soffredini, R., Del Ninno, E., Russo, A., Colombo, M.: Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. *Gastroenterol*;138:108-15. 2010.

Russo, M.W.: Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis. *Expert Rev Gastroenterol Hepatol*;4:535. 2010.

Samir, Gupta; Stephen, Bent; and Jeffrey, Kohlwes: Test Characteristics of alpha-Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C: A Systematic Review and

Critical Analysis". *Annals of Internal Medicine* 139 (1): 46–50.2003.

Sangiovanni, A., Prati, G.M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., Del Ninno, E., Morabito, A., Colombo, M.: The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. *Hepatology*;43:1303-10. 2006.

Sarrazin, C., Berg, T., Ross, R.S., Schirmacher, P., Wedemeyer, H., Neumann, U., Schmidt, H.H., Spengler, U., Wirth, S., Kessler, H.H., Peck-Radosavljevic, M., Ferenci, P., Vogel, W., Moradpour, D., Heim, M., Cornberg, M., Protzer, U., Manns, M.P., Fleig, W.E., Dollinger, M.M., Zeuzem, S.: Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. *Z Gastroenterol*;48:289-351. 2010.

Sato, Y., Nakata, K., Kato, Y., Shima, M., Ishii, N., Koji, T., Taketa, K., Endo, Y., Nagataki, S.: Early recognition oh hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. *N. Engl. J. Med.*,328: 1802-1806.1993.

Schaefer, A., Wittchen, H.U., Seufert, J., Kraus, M.R.: Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. *Int J Methods Psychiatr Res* ;16:186-201.2007.

- Schaefer, M., Engelbrecht, M.A., Gut, O., Fiebich, B.L., Bauer, J., Schmidt, F., Grunze, H., Lieb, K.:** Interferon alpha [IFNalpha] and psychiatric syndromes: a review. *Prog Neuropsychopharmacol Biol Psychiat*;26:731-46. 2002.
- Schaefer, M., Heinz, A., Backmund, M.:** Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? *Addiction*;99:1167-75. 2004.
- Schaefer, M., Hinzpeter, A., Mohmand, A., Janssen, G., Pich, M., Schwaiger, M., Sarkar, R., Friebe, A., Heinz, A., Kluschke, M., Ziemer, M., Gutsche, J., Weich, V., Halangk, J., Berg, T.:** Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. *Hepatology*;46:991-98. 2007.
- Schaefer, M., Mauss, S.:** Clinical management of Interferon-alpha-associated psychiatric side effects during hepatitis C treatment in patients with drug addiction. *Cur Drug Abuse Rev*;1:177-87. 2008.
- Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., Heldwein, W., Soyka, M., Grunze, H., Koenig, A., Loeschke, K.:** Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. *Hepatology*;37:443-51. 2003.

Schaefer, M., Schwaiger, M., Garkisch, A.S., Pich, M., Hinzpeter, A., Uebelhack, R., Heinz, A., van, Boemmel, F., Berg, T.: Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. *J Hepatol* ;42:793-8.2005.

Seyam, M.S., Freshwater, D.A., O'Donnell, K., Mutimer, D.J.: Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C. *J Viral Hepat*;12:531-5. 2005.

Shiffman, M.L., Diago, M., Tran, A., Pockros, P., Reindollar, R., Prati, D., Rodríguez-Torres, M., Lardelli, P., Blotner, S., Zeuzem, S. : Chronic hepatitis C in patients with persistently normal alanine transaminase levels. *Clinical Gastroenterology and Hepatology* 4 (5): 645–52. 2006.

Shiffman, M.L., Di, Bisceglie, A.M., Lindsay, K.L., Morishima, C., Wright, E.C., Everson, G.T., Lok, A.S., Morgan, T.R., Bonkovsky, H.L., Lee, W.M., Dienstag, J.L., Ghany, M.G., Goodman, Z.D., Everhart, J.E.; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group.: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. *Gastroenterol* ;126:1015-23;discussion 1947.2004.

Shiffman, M.L., Hofmann, C.M., Luketic, V.A., Sanyal, A.J.: Use of granulocyte macrophage colony stimulating factor alone or in

combination with interferon-alpha-2b for treatment of chronic hepatitis C. *J Hepatol*;28:382-89. 1998.

Shiffman, M.L., Ghany, M.G., Morgan, T.R., Wright, E.C., Everson, G.T., Lindsay, K.L., Lok, A.S., Bonkovsky, H.L., Di, Bisceglie, A.M., Lee, W.M., Dienstag, J.L., Gretch, D.R.: Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. *Gastroenterology*; 132:103. 2007.

Shiffman, M.L., Mihas, A.A., Millwala, F., Sterling, R.K., Luketic, V.A., Stravitz, R.T., Sanyal, A.J.: Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. *Am J Gastroenterol*; 102:761. 2007.

Shiffman, M.L., Mills, P., Moonka, D.K.: Enhanced efficacy of pegylated (40 kd) interferon alfa-2A (Pegasys) compared with interferon alfa-2A (Roferon-A) for chronic hepatitis C in blacks (abstract). *Hepatology*; 32:348A. 2000.

Shiffman, M.L., Salvatore, J., Hubbard, S., Price, A., Sterling, R.K., Stravitz, R.T., Luketic, V.A., Sanyal, A.J.: Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. *Hepatology*;46:371-9. 2007.

- Shiffman, M.L., Suter, F., Bacon, B.R., Nelson, D., Harley, H., Solá, R., Shafran, S.D., Barange, K., Lin, A., Soman, A., Zeuzem, S.; ACCELERATE Investigators.:** Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *N Engl J Med*;357:124-34. 2007.
- Shiojiri, N., Lemir,e J.M., Fausto, N.:** Cell lineages and oval cell progenitors in rat liver development. *Cancer Res* 51: 2611–20.1991.
- Sizaret, P., Martel, N., Tuyns, A., Reynaud, S.:** Mean alpha-fetoprotein values of 1,333 males over 15 years by age groups". *Digestion* 15 (2): 97–103.1977.
- S.L. Thomas, M-L. Newell, C.S. Peckham, A.E. Ades, A.J. Hall:** A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection, *International Journal of Epidemiology*, 27;1, pp. 108-117(10). 1998.
- Sterling, R.K., Stravitz, R.T., Luketic, V.A., Sanyal, A.J., Contos, M.J., Mills, A.S., Shiffman, M.L.:** A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. *Clin Gastroenterol Hepatol*;2:469-73. 2004.
- Su, A.I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K.A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., Cooke, M.P., Walker, J.R., Hogenesch, J.B.:** A gene atlas of the mouse and human protein-encoding transcriptomes". Diagram created by AndrewGNF. *Proc. Natl. Acad. Sci. U.S.A.* 101 (16): 6062–7.2004.

Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M.L., Bassendine, M., Spengler, U., Dore, G.J., Powell, E., Riordan, S., Sheridan, D., Smedile, A., Fragomeli, V., Müller, T., Bahlo, M., Stewart, G.J., Booth, D.R., George, J.: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet*; 41:1100. 2009.

Sulkowski, M.S., Shiffman, M.L., Afdhal, N.H., Reddy, K.R., McCone, J., Lee, W.M., Herrine, S.K., Harrison, S.A., Poordad, F.F., Koury, K., Deng, W., Noviello, S., Pedicone, L.D., Brass, C.A., Albrecht, J.K., McHutchison, J.G.; IDEAL Study Team: Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. *Gastroenterology*; 139:1602. 2010.

Svrtlih, N., Jevtovic, D., Simonovic, J., Delic, D., Dokic, L., Gvozdenovic, E., Boricic, I., Nesic, Z., Neskovic, G., Urban, V.: Older age at the time of liver biopsy is the important risk factor for advanced fibrosis in patients with chronic hepatitis C. *Hepatogastroenterology*; 54:2324-7. 2007.

Swain, M.G., Lai, M.Y., Shiffman, M.L., Cooksley, W.G., Zeuzem, S., Dieterich, D.T., Abergel, A., Pessôa, M.G., Lin, A., Tietz, A., Connell, E.V., Diago, M.: A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. *Gastroenterology*; 139:1593. 2010.

- Swain, M.G., Lai, M.Y., Shiffman, M.L.:** Durable sustained virological response after treatment with peginterferon alpha-2a alone or in combination with ribavirin: 5-year follow-up and the criteria of a cure. *J Hepatol*;46:S3-S3. 2007.
- Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., Ito, Y., Mita, E., Tanaka, E., Mochida, S., Murawaki, Y., Honda, M., Sakai, A., Hiasa, Y., Nishiguchi, S., Koike, A., Sakaida, I., Imamura, M., Ito, K., Yano, K., Masaki, N., Sugauchi, F., Izumi, N., Tokunaga, K., Mizokami, M.:** Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet*; 41:1105. 2009.
- Thompson, A.J., Muir, A.J., Sulkowski, M.S., Ge, D., Fellay, J., Shianna, K.V., Urban, T., Afdhal, N.H., Jacobson, I.M., Esteban, R., Poordad, F., Lawitz, E.J., McCone, J., Shiffman, M.L., Galler, G.W., Lee, W.M., Reindollar, R., King, J.W., Kwo, P.Y., Ghalib, R.H., Freilich, B., Nyberg, L.M., Zeuzem, S., Poynard, T., Vock, D.M., Pieper, K.S., Patel, K., Tillmann, H.L., Noviello, S., Koury, K., Pedicone, L.D., Brass, C.A., Albrecht, J.K., Goldstein, D.B., McHutchison, J.G.:** Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. *Gastroenterology* ;139:120.2010.

- Todros, L., Saracco, G., Durazzo, M., Abate, M.L., Touscoz, G., Scaglione, L., Verme, G., Rizzetto, M.:** Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. *Hepatology*;22:1374-78. 1995.
- Thomas, D.L., Thio, C.L., Martin, M.P., Qi, Y., Ge, D., O'Huigin, C., Kidd, J., Kidd, K., Khakoo, S.I., Alexander, G., Goedert, J.J., Kirk, G.D., Donfield, S.M., Rosen, H.R., Tobler, L.H., Busch, M.P., McHutchison, J.G., Goldstein, D.B., Carrington, M.:** Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature*; 461:798. 2009.
- Tohme, R.A., Holmberg, S.D.:** Is sexual contact a major mode of hepatitis C virus transmission?". *Hepatology* 52 (4): n/a. 2010.
- Tomasi, T.B. :**Structure and function of alpha-fetoprotein. *Annual review of medicine* 28: 453–65.1977.
- Tong, M.J., el-Farra, N.S., Reikes, A.R., Co, R.L.:** Clinical outcomes after transfusion-associated hepatitis C. *N. Engl. J. Med.*,332: 1463-1466.1995.
- Treviani, F., D'Intino, P., Morselli-Labate, AM., Mazzella, G., Accogli, E., Caraceni, P., Domenicali, M., De Notariis, S., Roda, E., Benardi, M.:** Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease:

influence of HBsAg and anti-HCV status. *J. Hepatol.*,34: 570-575.2001.

Tsamandas, A.C., Syrokosta, I., Thomopoulos, K., Zolota, V., Dimitropoulou, D., Liava, A., Coupoulou, A.A., Siagris, D., Petsas, T., Karatza, C., Gogos, C.A.: Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: a clinicopathologic study. *Liver Int* 26: 817–26.2006.

Valentine, A.D., Meyers, C.A.: Successful treatment of interferon-alpha-induced mood disorder with nortriptyline. *Psychosomat*;36:418-9. 1995.

Van, Thiel, D.H., Friedlander, L., Kania, R.J., Molloy, P.J., Hassanein, T., Faruki, H. A.: preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. *J Viral Hepat*;4:101-06. 1997.

Vandelli, C., Renzo, F., Romanò, L., Tisminetzky, S., De, Palma, M., Stroffolini, T., Ventura, E., Zanetti, A.: Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. *The American Journal of Gastroenterology* 99 (5): 855–9. 2004.

- Veldt, B.J., Heathcote, E.J., Wedemeyer, H., Reichen, J., Hofmann, W.P., Zeuzem, S., Manns, M.P., Hansen, B.E., Schalm, S.W., Janssen, H.L.:** Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. *Ann Intern Med*;147:677-84. 2007.
- Vescio, M.F., Longo, B., Babudieri, S., Starnini, G., Carbonara, S., Rezza, G., Monarca, R.:** Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. *Journal of Epidemiology and Community Health* 62 (4): 305–13. 2008.
- Wasley, A., Grytdal, S. and Gallagher, K.:** Centers for Disease Control and Prevention: Surveillance for acute viral hepatitis—United States, 2006. *MMWR SurveillSumm* 57. (2): 1-24.2008.
- Watanabe, T., Yamada, H., Morimura, Y., Abe, M., Motoyama, T., Sato, A.:** Ovarian Sertoli-Leydig cell tumor with heterologous gastrointestinal epithelium as a source of alpha-fetoprotein: a case report". *J. Obstet. Gynaecol. Res.* 34 (3): 418–21.2008.
- Wesche, B., Jaeckel, E., Trautwein, C., Wedemeyer, H., Falorni, A., Frank, H., von, zur, Mühlen, A., Manns, M.P., Brabant, G.:** Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. *Gut* ;48:378-83.2001.

Wiegand, J., Buggisch, P., Boecher, W., Zeuzem, S., Gelbmann, C.M., Berg, T., Kauffmann, W., Kallinowski, B., Cornberg, M., Jaeckel, E., Wedemeyer, H., Manns, M.P.; German HEP-NET Acute HCV Study Group.: Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. *Hepatology* ;43:250-56.2006.

Wiese, M., Berr, F., Lafrenz, M., Porst, H., Oesen, U.: Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. *Hepatology*;32:91-6. 2000.

Witzigmann, H., Geissler, F., Benedix, F., Thiery, J., Uhlmann, D., Tannapfel, A., Wittekind, C., Hauss, J.: Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. *Surgery*, 131: 34-43.2002.

Wong, J.B., Davis, G.L., McHutchison, J.G., Manns, M.P., Albrecht, J.K.; International Hepatitis Interventional Therapy Group.: Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. *Am J Gastroenterol*; 98:2354. 2003.

World Health Organization: Hepatitis C. Fact sheet N°164. Revised October 2000. Accessed March 5, 2009.

Wu, J.T., Book, L., Sudar, K.: Serum alpha fetoprotein (AFP) levels in normal infants". *Pediatric research* 15 (1): 50–2. 1981.

- Wu, J.T., Roan, Y., Knight, J.A. :** Serum levels of AFP in normal infants: their clinical and physiological significance". In Mizejewski GJ, Porter I. Alfa-Fetoprotein and Congenital Disorders. Academic Press. pp. 111–122.1985.
- Yin, L., Lynch, D., Ilic, Z., Sell, S.:** Proliferation and differentiation of ductular progenitor cells and littoral cells during the regeneration of the rat liver to Ccl4/2-AAF injury. *Histol Histopathol* 17: 65–81.2002.
- Younossi, Z.M., Nader, F.H., Bai, C., Sjogren, R., Ong, J.P., Collantes, R., Sjogren, M., Farmer, D., Ramsey, L., Terra, K., Gujral, H., Gurung, C., Srishord, M., Fang, Y.:** A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. *J Viral Hepat*;15:370-78. 2008.
- Zeuzem, S.:** Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? *Ann Intern Med*;140:370.2004.
- Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y., Cianciara, J., Ibranyi, E., Weiland, O., Noviello, S., Brass, C., Albrecht, J.:** Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. *J Hepatol*; 44:97. 2006.

Zeuzem, S., Diago, M., Gane, E., Reddy, K.R., Pockros, P., Prati, D., Shiffman, M., Farci, P., Gitlin, N., O'Brien, C.B., Lamour, F., Lardelli, P.; PEGASYS Study NR16071 Investigator Group.:
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
Gastroenterol ;127:1724-32.2004.

Zeuzem, S., Hultcrantz, R., Bourliere, M., Goeser, T., Marcellin, P., Sanchez-Tapias, J., Sarrazin, C., Harvey, J., Brass, C., Albrecht, J.: Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol;40:993-99. 2004.

Zhou, L., Liu, J., Luo, F.: Serum tumor markers for detection of hepatocellular carcinoma". World J Gastroenterol 12 (8): 1175–1181.2006.

Zignego, A.L., Ferri, C., Pileri, S.A., Caini, P., Bianchi, F.B.:
Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Digestive and Liver Disease 39 (1): 2–17. 2007.